Update on molecular pathology and role of liquid biopsy in nonsmall cell lung cancer.

ABSTRACT: Personalised medicine, an essential component of modern thoracic oncology, has been evolving continuously ever since the discovery of the epidermal growth factor receptor and its tyrosine kinase inhibitors. Today, screening for driver alterations in patients with advanced lung adenocarcinoma as well as those with squamous cell carcinoma and no/little history of smoking is mandatory. Multiplex molecular platforms are preferred to sequential molecular testing since they are less time- and tissue-consuming. In this review, we present the latest updates on the nine most common actionable driver alterations in nonsmall cell lung cancer. Liquid biopsy, a simple noninvasive technique that uses different analytes, mostly circulating tumour DNA, is an appealing tool that is used in thoracic oncolog

SUBMITTER: Abdayem P 

PROVIDER: S-EPMC9489045 | biostudies-literature | 2021 Sep

REPOSITORIES: biostudies-literature